July 23rd 2025
The solution missed the primary end point of the trial, which was complete resolution of debris after 6 weeks of twice-daily dosing.
Topline results from Ersa Phase 2a trial revealed by Tarsus
December 11th 2023TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
BREAKING NEWS: FDA approves lotilaner ophthalmic solution 0.25% for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
Cosmetic dangers: Part 2-Products banned by the FDA, worsen ocular surface disease
March 14th 2018In Part 2 of her three-part series on cosmetic dangers, Tracy Schroeder-Swartz, OD, MS, FAAO, focuses on the dangers found in cosmetics-particularly cosmetics banned by the FDA and those that may exacerbate ocular surface disease.
Preparing the periocular region for surgery
February 21st 2018Preparing a patient for ocular surgery can pose challenges with cosmetics being widely used. Marc Bloomenstein, OD, with the advice of Optometry Times Editorial Advisory Board member Whitney Hauser, OD, discusses the importance of properly preparing cosmetic users for eye surgery.
Why you should add upper lid eversion to your comprehensive exam
January 26th 2018Comprehensive ocular examinations can provide an OD with an inside look into a patient's health. Mile Brujic, OD, and David Kading, OD, discuss the importance of using upper eyelid eversion during the exam to unleash significant information about a patient's ocular surface and systemic health.